Table 2.

Adverse events experienced by patients with DPLN treated with prednisolone and either MMF or CTX-AZA

MMF and PrednisoloneCTX-AZA and PrednisoloneP Value
Leukopenia (<4 × 109/L)08 (25.8%)0.002
Gastrointestinal upset3 (9.1%)1 (3.2%)0.614
Severe hair loss09 (29.0%)0.001
Amenorrhea1 of 289 of 250.004
Withdrawal as a result of side effects1 (3.0%)3 (9.7%)0.347
Death02 (6.5%)0.231
Infection
    no. of patients with infections4 (12.5%)12 (40.0%)0.013
    no. of patients with infections that required hospitalization2 (6.3%)9 (30.0%)0.014
    herpes zoster2 (6.3%)5 (16.7%)0.249
Progressive renal impairment/end-stage renal failure4/0 (12.5%)1/2 (10.0%)1.000